Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages 304-313 , July 2007

Novel and Traditional Cardiovascular Risk Factors for Peripheral Arterial Disease in Incident-Dialysis Patients

  • Bernard G. Jaar

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • Nephrology Center of Maryland, Baltimore, MD
    • Corresponding Author InformationAddress correspondence to Bernard G. Jaar, MD, MPH, Johns Hopkins Medical Institutions, Division of Nephrology, 2024 E. Monument Street, Suite 2-500, Baltimore, MD 21205.
    • ,
  • Laura C. Plantinga

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    • ,
  • Brad C. Astor

      Affiliations

    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • ,
  • Nancy E. Fink

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • ,
  • Craig Longenecker

      Affiliations

    • Department of Community Medicine, Kuwait University, Safat, Kuwait
    • ,
  • Russell P. Tracy

      Affiliations

    • Laboratory for Clinical Biochemistry Research, Department of Pathology, University of Vermont, Colchester, VT
    • Dr Tracy is supported in part by HL 46696 and HL 58329.
    • ,
  • Santica M. Marcovina

      Affiliations

    • Northwest Lipid Research Laboratories, University of Washington, Seattle, WA
    • ,
  • Neil R. Powe

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • Dr. Powe is supported in part by K24-DK-02643 (NIDDK).
    • ,
  • Josef Coresh

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
    • Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
    • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
    • Dr. Coresh is supported in part as an American Heart Association established investigator (01-4019-7N).

References 

  1. U.S. Renal Data System: USRDS 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
  2. O’Hare A, Johansen K. Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol. 2001;12:2838–2847
  3. O’Hare AM, Hsu CY, Bacchetti P, et al. Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol. 2002;13:497–503
  4. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58:353–362
  5. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425–428
  6. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg. 1997;11:217–223
  7. Cheng SW, Ting AC, Wong J. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg. 1997;14:17–23
  8. Miskulin DC, Athienites NV, Yan G, et al. Comorbidity assessment using the Index of Coexistent Diseases in a multi-center clinical trial. Kidney Int. 2001;60:1498–1510
  9. Athienites NV, Miskulin DC, Fernandez G, et al. Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial. 2000;13:320–326
  10. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clin Chem. 1997;43:52–58
  11. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246–255
  12. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43–52
  13. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481–2485
  14. Localio AR, Berlin JA, Ten Have TR, et al. Adjustments for center in multicenter studies: an overview. Ann Intern Med. 2001;135:112–123
  15. U.S. Renal Data System: USRDS 1999 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
  16. Criqui MH. Peripheral arterial disease—epidemiological aspects. Vasc Med. 2001;6:3–7
  17. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: A cross-sectional study. J Am Soc Nephrol. 2001;12:1516–1523
  18. U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
  19. Fishbane S, Youn S, Flaster E, et al. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis. 1996;27:668–672
  20. Ono K, Tsuchida A, Kawai H, et al. Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003;14:1591–1598
  21. Testa A, Ottavioli JN. Ankle-arm blood pressure index (AABPI) in hemodialysis patients. Arch Mal Coeur Vaiss. 1998;91:963–965
  22. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk. Vasc Med. 1997;2:221–226
  23. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?. Circulation. 1999;100:96–102
  24. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113:2623–2629
  25. Yeun J, Levine R, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  26. Boger CA, Gotz A, Stubanus M, et al. C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease. Kidney Int. 2005;68:217–227
  27. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein(a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59–67
  28. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195–2199
  29. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care. 2004;27:517–521
  30. Auguet T, Senti M, Rubies-Prat J, et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: Influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant. 1993;8:1099–1103
  31. Dieplinger H, Lackner C, Kronenberg F, et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest. 1993;91:397–401
  32. Kronenberg F, Konig P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–120
  33. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in eialysis patients. J Am Soc Nephrol. 2005;16:1794–1802
  34. Lye WC, Hughes K, Leong SO, et al. Lipoprotein (a) levels and clinical correlations in CAPD patients. Adv Perit Dial. 1995;11:131–133
  35. Kronenberg F, Mundle M, Langle M, et al. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis. 2003;41:140–148
  36. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554–2558
  37. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389
  38. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
  39. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease (The European Concerted Action Project). JAMA. 1997;277:1775–1781
  40. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int. 1997;52:10–20
  41. Moustapha A, Gupta A, Robinson K, et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int. 1999;55:1470–1475
  42. Chauveau P, Chadefaux B, Coude M, et al. Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electrolyte Metab. 1992;18:196–198
  43. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121–125
  44. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748
  45. Manns B, Burgess E, Hyndman ME, et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis. 1999;34:669–677

 CHOICE is supported by RO1-HL-62985 (National Heart, Lung, and Blood Institute [NHLBI]) and RO1-DK-59616 (National Institute of Diabetes & Digestive & Kidney Diseases [NIDDK]).

PII: S1548-5595(07)00059-6

doi: 10.1053/j.ackd.2007.04.005

Advances in Chronic Kidney Disease
Volume 14, Issue 3 , Pages 304-313 , July 2007

Article Tools

* Image Usage & Resolution